Oncology Corporate Profile
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|LN-145||adoptive cell transfer (ACT) therapy||Cervical cancer||II|
|LN-145||adoptive cell transfer (ACT) therapy||Head & Neck cancer||II|
|LN-144||adoptive cell transfer (ACT) therapy||Melanoma||II|
View additional information on product candidates here »